Skip to content

Tolerance of Infants Fed a Hydrolysate Formula

Tolerance of Infants Fed a Hydrolysate Formula Manufactured With a New Processing Method

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03628183
Enrollment
51
Registered
2018-08-14
Start date
2018-08-28
Completion date
2018-11-23
Last updated
2018-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Tolerance

Brief summary

This is a prospective, randomized, multicenter study to assess the tolerance of infant formulas.

Interventions

OTHERHydrolysate Infant Formula 1

Feed ad lib

OTHERHydrolysate Infant Formula 2

Feed ad lib

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 14 Days
Healthy volunteers
Yes

Inclusion criteria

* Subject is judged to be in good health * Singleton from a full-term birth * Birth weight was \> or = to 2490 g * Between 0 and 14 days of age at enrollment * Parent(s) confirm their intention to feed their infant the assigned study product as the sole source of nutrition for the duration of the study * Parent(s) confirm their intention not to administer vitamin or mineral supplements, solid foods or juices to their infant from enrollment through the duration of the study * Subject's parent(s) has voluntarily signed and dated an Informed Consent Form (ICF)

Exclusion criteria

* An adverse maternal, fetal or subject medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development. * Subject is taking and plans to continue medications, home remedies, herbal preparations or rehydration fluids that might affect gastrointestinal (GI) tolerance * Subject participates in another study that has not been approved as a concomitant study * Subject has an allergy or intolerance to any ingredient in the study product * Subject has been treated with antibiotics within 2 weeks prior to enrollment

Design outcomes

Primary

MeasureTime frameDescription
Stool CharacteristicsStudy Day 1 - Study Day 21Parent completed diary

Secondary

MeasureTime frameDescription
Formula IntakeStudy Day 1 - Study Day 21Parent completed diary
WeightStudy Day 1 - Study Day 21Scale
LengthStudy Day 1 - Study Day 21Length board

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026